PHS
KROS icon

PFM Health Sciences’s Keros Therapeutics KROS Stock Holding History

PFM Health Sciences’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-104,323
Closed -$1.06M – 68
2025
Q1 		$1.06M Hold
104,323
– – 0.08% 59
2024
Q4 		$1.65M Buy
104,323
+3,273
+3% +$170K 0.1% 75
2024
Q3 		$5.87M Buy
101,050
+67,695
+203% +$3.34M 0.33% 48
2024
Q2 		$1.52M Buy
+33,355
New +$1.79M 0.08% 72
2023
Q3 		– Sell
-20,350
Closed -$818K – 81
2023
Q2 		$818K Hold
20,350
– – 0.03% 81
2023
Q1 		$869K Buy
20,350
+4,351
+27% +$220K 0.04% 76
2022
Q4 		$768K Buy
+15,999
New +$747K 0.03% 82

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PFM Health Sciences's KROS Position: Q2 2025 in Review

PFM Health Sciences sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 104,323 shares — an estimated $1.06M sold.

PFM Health Sciences first reported a position in KROS in Q4 2022 and held it in 7 quarters. The position peaked at $5.87M in Q3 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • PFM Health Sciences reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • PFM Health Sciences sold 104,323 Keros Therapeutics shares in Q2 2025, an estimated $1.06M.
  • PFM Health Sciences first reported a position in Keros Therapeutics in Q4 2022 and held it in 7 quarters.
  • PFM Health Sciences's Keros Therapeutics position peaked at $5.87M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.